|
 The company's stock jumped 21 percent to $10.90 in
trading before the bell on Tuesday.
The oral drug, BCX4161, was being evaluated against a placebo in
patients with hereditary angioedema (HAE) – a genetic disease
characterized by sudden attacks of swelling of the skin or the
mucous membranes, which can be disfiguring, painful and
life-threatening.
Those who received the drug had an average rate of 0.82 attacks per
week, compared with 1.27 for those given a placebo, BioCryst said in
a statement.
The study tested the safety and efficacy of a 400 mg dose of the
drug administered three times a day for 28 days.
The patients given the drug went 22 days on average without an
attack, compared with 19 days for those given the placebo, the
drugmaker said.
BioCryst, which is also developing drugs for infectious diseases and
gout, currently sells its influenza treatment Peramivir in Japan and
Korea.
The Research Triangle Park, North Carolina-based company's shares
closed at $9.005 on the Nasdaq on Friday.
[to top of second column] |
(Reporting by Esha Dey and Natalie Grover in Bangalore; Editing by
Savio D'Souza)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
